Description and Brand Names
Drug information provided by: Merative, Micromedex®
US Brand Name
Pertuzumab, trastuzumab, and hyaluronidase-zzxf combination injection is used first together with other cancer medicines to treat HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 centimeters in diameter or node positive) as part of a complete treatment plan for early breast cancer. It is also used after an initial treatment plan to treat HER2-positive early breast cancer which has a high risk of occurring again.
Pertuzumab, trastuzumab, and hyaluronidase-zzxf combination injection is also used together with docetaxel to treat HER2-positive metastatic (cancer that has spread) breast cancer in patients who have not previously received cancer treatment.
Pertuzumab, trastuzumab, and hyaluronidase-zzxf combination prevents the growth of some tumors that produce extra amounts of a certain substance known as the HER2 protein. It should only be used in patients whose tumors have been shown to produce extra amounts of this protein (HER2 overexpression).
This medicine is to be given only by or under the direct supervision of your doctor.
This product is available in the following dosage forms: